NO20062432L - Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav - Google Patents
Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse deravInfo
- Publication number
- NO20062432L NO20062432L NO20062432A NO20062432A NO20062432L NO 20062432 L NO20062432 L NO 20062432L NO 20062432 A NO20062432 A NO 20062432A NO 20062432 A NO20062432 A NO 20062432A NO 20062432 L NO20062432 L NO 20062432L
- Authority
- NO
- Norway
- Prior art keywords
- statin
- carrier
- mediated transport
- present
- formulations
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 6
- 230000001404 mediated effect Effects 0.000 title abstract 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 229960000672 rosuvastatin Drugs 0.000 abstract 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51677003P | 2003-11-04 | 2003-11-04 | |
| US10/967,167 US8987322B2 (en) | 2003-11-04 | 2004-10-19 | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| PCT/IB2004/003849 WO2005041939A1 (fr) | 2003-11-04 | 2004-10-29 | Formulations pharmaceutiques de statines de diffusion assistee par des porteurs et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062432L true NO20062432L (no) | 2006-08-04 |
Family
ID=34556205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062432A NO20062432L (no) | 2003-11-04 | 2006-05-29 | Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8987322B2 (fr) |
| EP (2) | EP1682095B1 (fr) |
| JP (1) | JP2007510714A (fr) |
| AU (1) | AU2004284884A1 (fr) |
| CA (1) | CA2543716C (fr) |
| ES (2) | ES2509869T3 (fr) |
| IL (1) | IL175134A0 (fr) |
| NO (1) | NO20062432L (fr) |
| WO (1) | WO2005041939A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| CA2628666A1 (fr) * | 2005-11-21 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Formulation d'atorvastatine |
| WO2007071357A2 (fr) * | 2005-12-20 | 2007-06-28 | Lek Pharmaceuticals D.D. | Composition pharmaceutique |
| WO2007103453A1 (fr) * | 2006-03-06 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | Compositions à base d'ézétimibe |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
| WO2008154339A2 (fr) * | 2007-06-08 | 2008-12-18 | Addrenex Pharmaceuticals, Inc. | Formulation à libération prolongée et procédé de traitement d'un dérèglement adrénergique |
| US20090082315A1 (en) * | 2007-09-05 | 2009-03-26 | Raif Tawakol | Compositions and Methods for Controlling Cholesterol Levels |
| TR200800269A2 (tr) * | 2008-01-15 | 2009-08-21 | Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. | Stabil farmasötik formülasyon ve hazırlama yöntemleri |
| TWI391150B (zh) * | 2008-01-22 | 2013-04-01 | Taiwan Biotech Co Ltd | 腸溶性長效塗覆芯與藥物劑型及其製造方法 |
| WO2009095934A1 (fr) * | 2008-01-30 | 2009-08-06 | Lupin Limited | Formulations à libération modifiée d’inhibiteurs de la hmg-coa réductase |
| US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| EP2661273A4 (fr) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | Compositions pharmaceutiques de fer pour administration orale |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4088884A (en) * | 1976-01-26 | 1978-05-09 | The United States Of America As Represented By The Secretary Of The Navy | Wide aperture optical communications detector |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4557925A (en) | 1982-07-08 | 1985-12-10 | Ab Ferrosan | Membrane-coated sustained-release tablets and method |
| SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
| US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
| CA2045428A1 (fr) | 1990-06-26 | 1991-12-27 | Alfred W. Alberts | Methode pour favoriser la reduction de la cholesterolemie |
| US6764697B1 (en) * | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| CO5140079A1 (es) | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP2002538202A (ja) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
| US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| AU5340101A (en) * | 2000-04-11 | 2001-10-23 | Atherogenics Inc | Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| MXPA04006780A (es) | 2002-01-11 | 2005-06-08 | Athpharma Ltd | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. |
| US20040132802A1 (en) | 2002-09-03 | 2004-07-08 | Jackie Butler | Pharmaceutical formulations and methods for modified release of statin drugs |
| US20040132806A1 (en) | 2002-09-03 | 2004-07-08 | Jackie Butler | Pravastatin pharmaceutical formulations and methods of their use |
-
2004
- 2004-10-19 US US10/967,167 patent/US8987322B2/en not_active Expired - Fee Related
- 2004-10-29 ES ES04791793.5T patent/ES2509869T3/es not_active Expired - Lifetime
- 2004-10-29 CA CA2543716A patent/CA2543716C/fr not_active Expired - Fee Related
- 2004-10-29 EP EP04791793.5A patent/EP1682095B1/fr not_active Expired - Lifetime
- 2004-10-29 JP JP2006538993A patent/JP2007510714A/ja active Pending
- 2004-10-29 EP EP10185149.1A patent/EP2319501B1/fr not_active Expired - Lifetime
- 2004-10-29 AU AU2004284884A patent/AU2004284884A1/en not_active Abandoned
- 2004-10-29 WO PCT/IB2004/003849 patent/WO2005041939A1/fr not_active Ceased
- 2004-10-29 ES ES10185149.1T patent/ES2500924T3/es not_active Expired - Lifetime
-
2006
- 2006-04-24 IL IL175134A patent/IL175134A0/en unknown
- 2006-05-29 NO NO20062432A patent/NO20062432L/no not_active Application Discontinuation
-
2015
- 2015-02-23 US US14/629,232 patent/US20150164893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1682095A1 (fr) | 2006-07-26 |
| US8987322B2 (en) | 2015-03-24 |
| CA2543716C (fr) | 2016-05-31 |
| US20050119331A1 (en) | 2005-06-02 |
| JP2007510714A (ja) | 2007-04-26 |
| EP2319501B1 (fr) | 2014-06-18 |
| CA2543716A1 (fr) | 2005-05-12 |
| ES2509869T3 (es) | 2014-10-20 |
| WO2005041939A1 (fr) | 2005-05-12 |
| AU2004284884A1 (en) | 2005-05-12 |
| US20150164893A1 (en) | 2015-06-18 |
| EP1682095B1 (fr) | 2014-07-02 |
| IL175134A0 (en) | 2006-09-05 |
| EP2319501A1 (fr) | 2011-05-11 |
| ES2500924T3 (es) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
| NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
| NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
| NO20074619L (no) | Spiro-oksindolforbindelser og deres anvendelse som medikamenter | |
| DE60219954D1 (de) | Neue Indol-2-on Derivate | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| ATE369355T1 (de) | Pyrimidinamid derivate und deren verwendung | |
| WO2004045593A3 (fr) | Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux | |
| EA200970435A1 (ru) | Лечение общих расстройств развития | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| NO20065904L (no) | Terapeutiske forbindelser | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| NO20023486D0 (no) | Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer | |
| WO2003020214A3 (fr) | Composes derives des acides biliaires permettant d'ameliorer l'absorption orale et la biodisponibilite systemique de medicaments | |
| NO20021437L (no) | Fremgangsmate til forebyggelse av colorektal kreft | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| NO20074661L (no) | Anvendelse av en forbindelse | |
| DE60121695D1 (de) | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen | |
| CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
| NO20050933L (no) | Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav | |
| BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
| EA200600597A1 (ru) | Полиэфирные производные бреветоксина в качестве средств лечения кистозного фиброза, дисфункции реснитчатого эпителия и болезней лёгких | |
| NO20034381D0 (no) | Kombinasjonsdose av cyklooksygenaseinhibitor, en vitamin-D3- omfattende analog og metabolitter derav, og/eller kalsium for forebyggelse avepitelial kreft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |